Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

1.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.

Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB.

Blood. 2011 Oct 13;118(15):4070-8. doi: 10.1182/blood-2011-03-341693. Epub 2011 Aug 9.

PMID:
21828142
[PubMed - indexed for MEDLINE]
Free Article
2.

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A.

Blood. 2009 Jul 16;114(3):709-18. doi: 10.1182/blood-2009-02-204156. Epub 2009 Apr 29.

PMID:
19403889
[PubMed - indexed for MEDLINE]
Free Article
3.

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.

Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Leoni P, Bacigalupo A.

Blood. 2013 Dec 12;122(25):4111-8. doi: 10.1182/blood-2013-05-494278. Epub 2013 Oct 23.

PMID:
24152907
[PubMed - indexed for MEDLINE]
Free Article
4.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26.

PMID:
18307562
[PubMed - indexed for MEDLINE]
5.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2006 Mar 1;24(7):1195-203.

PMID:
16505440
[PubMed - indexed for MEDLINE]
Free Article
6.

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A.

Leuk Res. 2006 Aug;30(8):965-70. Epub 2006 Jan 6.

PMID:
16406016
[PubMed - indexed for MEDLINE]
7.

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.

Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, Jouet JP, Yakoub-Agha I.

Blood. 2009 Jul 16;114(3):719-22. doi: 10.1182/blood-2009-02-204750. Epub 2009 Mar 16.

PMID:
19289852
[PubMed - indexed for MEDLINE]
Free Article
8.

Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O.

Int J Hematol. 2007 Oct;86(3):233-7. Review.

PMID:
17988989
[PubMed - indexed for MEDLINE]
9.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

PMID:
18955458
[PubMed - indexed for MEDLINE]
Free PMC Article
10.
11.

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11.

PMID:
19211938
[PubMed - indexed for MEDLINE]
Free Article
12.

A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.

Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E.

Eur J Cancer. 2009 Sep;45(13):2352-9. doi: 10.1016/j.ejca.2009.05.008. Epub 2009 Jun 6.

PMID:
19505817
[PubMed - indexed for MEDLINE]
13.

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease.

Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, Miyamoto T, Takenaka K, Akashi K, Harada M.

Int J Hematol. 2009 Sep;90(2):253-60. doi: 10.1007/s12185-009-0370-x. Epub 2009 Jun 20.

PMID:
19543951
[PubMed - indexed for MEDLINE]
14.
15.

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Bone Marrow Transplant. 2007 Aug;40(3):273-7. Epub 2007 Jun 4.

PMID:
17549053
[PubMed - indexed for MEDLINE]
16.

Daclizumab for children with corticosteroid refractory graft-versus-host disease.

Teachey DT, Bickert B, Bunin N.

Bone Marrow Transplant. 2006 Jan;37(1):95-9.

PMID:
16247417
[PubMed - indexed for MEDLINE]
17.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P.

Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.

PMID:
17715389
[PubMed - indexed for MEDLINE]
Free Article
18.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
[PubMed - indexed for MEDLINE]
19.

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.

Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H.

Cancer. 2007 Sep 15;110(6):1295-302.

PMID:
17623836
[PubMed - indexed for MEDLINE]
Free Article
20.

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.

Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS.

Prostate. 2005 Feb 1;62(2):115-22.

PMID:
15389797
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk